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Synopsis: Among HIV-seropositive women, bacterial vaginosis was not associated with an increased 





Objective: Both bacterial vaginosis (BV) and human papillomavirus (HPV) infections are common 
in HIV positive women. HPV/HIV coinfection is known to increase the risk of high-grade squamous 
intra-epithelial lesions (HSIL). The effect of BV on risk of HSIL, however, is unknown among HIV-
seropositive individuals.  
Method: A hospital-based prospective cohort study of HIV-seropositive women was conducted in 
Johannesburg, South Africa from 2005 to 2009. Multivariate log-binomial and Poisson regressions 
were used to estimate prevalence and rate ratios, respectively. 
Results: Among 1,954 HIV-seropositive women, the baseline prevalence of HSIL was 17%. BV 
prevalence was high (54%) and showed no association with prevalent HSIL (adjusted prevalence 
ratio: 1.12, 95% CI: 0.92, 1.35) nor with cervical lesion progression at follow-up visit (N=503) 
(adjusted rate ratio: 1.00, 95% CI: 0.65, 1.53).  
Conclusion: Among HIV-seropositive women, BV was not associated with an increased risk of HSIL 




          In 2008, an estimated 16 million women were living with HIV infection worldwide, the 
majority of which occurred in less-developed countries[1].  In South Africa, the 2008 estimated 
prevalence of HIV infection in the general population was 11%. An estimated 60% of those cases 
were in women, with HIV prevalence as high as 33% among women aged 20-34 years[2].  Regardless 
of HIV status, cervical cancer is the leading cause of cancer in African women, and the second most 
common in South African women[3].  Moreover, HIV-related immunosuppression is associated with 
a higher prevalence and incidence of precancerous cervical lesions as well as invasive cervical cancer 
[4]. The high prevalence of HIV in South African women combined with the high prevalence of 
precancerous high grade cervical lesions underscores the need to better understand the etiology of 
cervical cancer in this high-risk population.  
           Human papillomavirus (HPV) infection is well-documented as the central causal agent of 
cervical cancer. Most women infected with high risk HPV types, however, do not develop high grade 
cervical lesions and cancer[5]. Other factors acting in conjunction with HPV infection are likely 
involved in promoting the oncogenic capabilities of HPV, leading to the development of cancer. Co-
infection of HPV with bacterial vaginosis (BV) has been suggested to advance this process and, for 
more than 25 years, has been considered a possible risk factor for cervical cancer development[6-16]. 
Only a few studies, however, have investigated the relationship between BV and cervical neoplasia in 
an HIV-seropositive study population, with inconsistent results [10, 16].   
We therefore present here results of the association between BV and high grade squamous 






         Study participants were enrolled in the South Africa Cervical Cancer Cohort (SACCC), an on-
going observational study.  HIV-seropositive women, 18-65 years of age, were recruited from the 
Themba Lethu Clinic, an HIV outpatient clinic in a teaching hospital affiliated with the University of 
Witwatersrand in Johannesburg.  All women consecutively enrolled between January 2005 and 
September of 2009 were included. Women were ineligible to participate in this study if they had 
undergone a hysterectomy or prior cone biopsy treatment for cervical lesions or were severely ill (per 
investigator judgment). Women with symptomatic STIs (e.g., excessive vaginal discharge) became 
study-eligible following treatment for the STIs; women who were pregnant became eligible 6 weeks 
after delivery.  
         Eligible women first attended an educational session on cervical cancer screening presented in 
English or Zulu, and those interested in participating gave written informed consent.  All study 
protocols were reviewed and cleared by the University of Witwatersrand Human Research Ethics 
Committee and, for secondary data analysis, from the University of North Carolina.  All study 
participants were treated according to the HIV South African Guidelines on Comprehensive HIV and 
AIDS Care, Management and Treatment, which initiates highly active antiretroviral therapy 
(HAART) at WHO stage 4 or CD4 count < 200 cells/mm3. Antibiotic treatment was offered to all 
women presenting with BV.  
          Medical history and potential risk factor information was obtained through interview at study 
entry and at follow-up visit. A medical exam, including a blood test, was performed to assess CD4 
counts and the presence of symptomatic STIs.  A pelvic exam was performed to collect samples for 
Pap analysis.  For Pap analysis, cervical cells were collected using an endocervical brush.  
Conventional cervical smears were performed because liquid-based cytology is currently not 
available in the public health sector of South Africa.  Cytology slides were read and analyzed 
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according to the Bethesda 2001 reporting guidelines, categorized as negative for intraepithelial 
lesions or malignancy; atypical cells of undetermined significance (ASC-US); atypical squamous 
cells, cannot exclude high grade (ASC-H); atypical glandular cells (AGC); low-grade squamous 
intraepithelial lesions (LSIL); high-grade SIL (HSIL); or squamous cell carcinoma (SCC). For quality 
control, 10% of the cytology slides were sent to the University of North Carolina for a blinded second 
reading on two different occasions and a concordance of 81-85% was observed.  The conventional 
cytology slides were also assessed for the presence or absence of clue cells, indicative of BV (Figure 
1), as well as for trichomoniasis and candidiasis.   
The outcome for cross-sectional analysis was the presence of HSIL, ASC-H, or SCC; 
collectively, this outcome was designated HSIL+.  The non-outcome category included all other 
diagnoses, and was designated <HSIL. The outcome for the analysis of rate of progression of cervical 
disease was any increase in grade of lesion, ordered from least to most serious in the following three 
categories: (1) negative; (2) LSIL, ASC-US, or AGC; and (3) HSIL, ASC-H, or SCC (collectively, 
HSIL+). Our main analysis categorized ASC-US and AGC results as LSIL, but we also explored 
categorizing these results as negative and excluding these results entirely.  
There were two main analyses. First, we assessed the cross-sectional association of BV and 
HSIL+ status using prevalence ratios (PRs) and corresponding 95% confidence intervals (CIs). 
Prevalence ratios were estimated with multivariable log-binomial regression.  
Second we assessed the effect of baseline BV on rate of any cervical lesion progression (from 
negative to LSIL, negative to HSIL+ or from LSIL to HSIL+) by first follow-up visit. In addition, we 
assessed the effect of BV at baseline and at first follow-up visit, indicative of persistent BV, on 
cervical lesion progression. Progression analysis was restricted to women who were HSIL-negative at 
baseline, and to women whose first follow-up visit was at least six months after baseline; this latter 
condition was employed to exclude apparent progressions which were more likely to be measurement 
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error, as insufficient time had passed for a true progression to occur. We estimated adjusted incidence 
rate ratios (IRRs) and 95% CIs using Poisson regression with the log of follow-up time (time between 
visits) as the offset.  
In both analyses, we identified potential confounding variables using directed acyclic graphs 
informed by literature. Covariates included CD4 count (categorized as <200; 200-500; and >500 
cells/mm3), trichomoniasis or candidiasis infection (yes/no), education level (< grade 8;  grades 8-12 
years; > grade 12), unemployed (yes/no), current smoking (yes/no), current use of snuff (none; 1-3 
/day; >3 /day), age of sexual debut (<15; 15-18;19-21; >21),  lifetime number of sexual partners (<5; 
5-10; >10), condom use at last act (yes/no), and age (included as a continuous linear and quadratic 
term).  
In both regression modeling processes, covariates were maintained in the models through 
backwards elimination based on a likelihood ratio test p-value of <0.1, although age and CD4 count 
were maintained in all models. Less than 4% of the study population had missing values for one or 
more covariates in the full multivariate model, and thus were excluded from final analyses. All 
analyses were performed using SAS 9.2 (SAS Corporation, Cary, NC). 
 
RESULTS 
         A total of 1,954 women with baseline cytology contributed to analysis. Of these women, 1,063 
(54%) had BV at baseline (Table 1). Median age was 34 (range 18-65), and did not differ by baseline 
BV status. Most of the study population was of African ethnicity (98%) with the remainder 
identifying as mixed African ethnicity (2%).  Approximately one-third of the women had 
matriculated from high school, with the majority receiving 8-12 years of education, and half (49%) 
were unemployed. The median CD4 count for the population was 247 cells/mm3 (interquartile range 
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138-390 cells/mm3), and was slightly lower for women with BV at baseline compared to women 
without BV at baseline. While 54% of the population had BV, trichomoniasis and candidiasis 
infections were relatively less common at 4% and 5%, respectively. Few women reported current 
smoking (4%) or snuff use (10%). Most women reported no current hormonal contraceptive use 
(86%), were between 15-18 years of age at their sexual debut (61%), had 4 or less lifetime partners 
(61%), and reported current condom use (73%).  
The overall baseline prevalence of cervical lesions was 15% for LSIL and 17% for HSIL 
(Figure 2). ASC-US and ACG made up approximately 21% of the diagnoses, with the majority of 
these being ASC-US cases. Three cases of cervical cancer were observed; these women were treated 
immediately.  Just under half of the women (47%) had negative cytology at baseline. A 12% higher 
prevalence of HSIL+ was observed among HIV-seropositive women with BV (adjusted PR: 1.12, 
95% CI: 0.92, 1.35, versus BV-negative), after adjustment for age, CD4 count, trichomoniasis or 
candidiasis infection, current hormone contraceptive use, and current smoking (Table 2). 
A total of 503 women with <HSIL diagnosed at baseline had a follow-up visit six or more 
months from their initial study visit. The median time for the follow-up visit was 1.2 years (IQR 1.1 
to 1.4 years). Median follow-up time for women with and without BV at baseline was the same (1.2 
years for both).  
When including women with an ASC-US or AGC diagnosis as LSIL, 87 women showed 
progression. Women with BV at baseline were equally as likely as women without BV at baseline to 
show cervical lesion progression at their follow-up visit, after adjustment for CD4 count, age, and age 
at sexual debut (adjusted IDR: 1.00, 95% CI:0.65, 1.53; shown in Table 3). A similar association was 
observed between persistent BV (women with BV at both baseline and first follow-up) and lesion 
progression. Women with persistent BV were 1.2 times as like as women without persistent BV to 
show cervical lesion progression at their follow-up visit, after adjustment for CD4 count, age, and age 
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at sexual debut (adjusted IDR 1.18, 95% CI:0.73, 1.92; data not shown).  The effect estimates for BV 
at baseline as the exposure are slightly greater when women with ASC-US and AGC are grouped 
with negative cytology results (adjusted IDR: 1.27, 95% CI: 0.76, 2.11) and also when women with 
ASC-US and AGC are excluded from the analysis entirely (adjusted IDR: 1.78, 95% CI: 0.84, 3.79).  
However, these later results were statistically insignificant and less precise.   
 
DISCUSSION 
            Among 1,954 HIV-seropositive women, prevalent BV was not associated with prevalent high 
grade cervical lesions or with the progression of cervical lesions at their next visit. Further, no 
association was seen between persistent BV and cervical lesion progression. These study results are 
distinctive in their focus on BV and high grade cervical lesions and cervical cancer within an HIV-
seropositive population in the resource-limited nation of South Africa.  
A high prevalence of high-grade cervical lesions (17%) was observed among these HIV-
seropositive women at baseline visit. This prevalence of HSIL is higher than that observed for HIV-
seropositive populations in France and French Guyana (7.5%), a 12-nation, European cohort (2.8%), 
Finland (5%), and Zimbabwe (3.4%)[10, 17-19], but lower than that found for an HIV-seropositive 
population in Zambia (32.6%)[20].  Differences in HSIL prevalence across studies may be 
attributable in part to differences in HIV disease stage. Both our study population and the study group 
in Zambia were conducted among HIV-seropositive women with relatively lower median CD4 count 
(247 and 165 cells/mm3, respectively) than that of the 12-nation European cohort (378 cells/mm3).  
The lack of an association observed here for BV with high grade cervical lesions differs from 
the positive association found in a previous study in an HIV-seropositive population in Finland[10], 
and in populations from Brazil, Holland, and South Africa, in which HIV-status was unrecorded[7-9, 
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14]. Our results are consistent, however, with those from two European studies with HIV status 
unknown[13, 15], and three studies in the US, two with unknown HIV-status[6, 12] and one with 
HIV-seropositive participants[16].  Four of these studies also assessed the association between BV 
and HPV infection, with only one[16] finding a positive association with HPV infection[6, 12, 15]. 
Although different methods were used to diagnose BV across studies (clinical diagnosis (pH >4.5, 
positive amine test, positive gram stain, and characteristic vaginal discharge)[9, 12, 13, 15], gram 
stain[6, 16], or from Pap slides[7, 8, 10, 14]), in our view, the disparate association results do not 
appear to be explained by differences in methods to ascertain BV infection.     
A high proportion of women surveyed had prevalent BV (54%).  Prevalence of BV has been 
shown to range from 5-35% in the US and Europe, and from 18-70% in African nations[21]. 
Although there is debate as to if BV is a sexually transmitted infection (STI),  BV is most common in 
women of reproductive age and has been associated with a higher number of reported sexual partners, 
the presence of other STIs, and less frequent condom use[22].  Estimates of association between BV 
and high grade lesions observed here was similar in the crude and multivariate analyses, suggesting 
that in this population, the association between BV and high grade cervical lesions is not notably 
confounded by shared demographic or sexual behavioral risk factors. Confounding by unmeasured 
factors, however, cannot be ruled out definitively. 
It has been postulated that BV influences cervical lesion and cancer development both 
through an increase in vaginal nitrosamines and through a change in the vaginal cytokine profile[23]. 
Carcinogenic nitrosamines increase the probability of DNA damage and an altered cytokine profile 
may reduce the immune system’s ability to eliminate HPV infection. Both changes may create an 
environment more conducive to cancer development. HIV-seropositivity also alters vaginal immune 
capabilities and cytokine profiles, further complicating the etiological mechanisms suggested to link 
BV to cervical precancer[24]. The lack of an association between BV and high grade cervical lesions 
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observed here suggests a need to further consider the biological response to BV and its proposed 
relationship to cervical cancer in HIV-seropositive women.  
The strengths of this study include its large size and its focus on an HIV-seropositive 
population in the resource-limited nation of South Africa. Few studies have addressed this vulnerable 
population and assessed the development and progression of precancerous lesions among HIV-
seropositive women. A key limitation of this study is the use of Pap slides for diagnosis of BV. The 
sensitivity for BV diagnosis from Pap slides ranges from 55-93%, with specificity ranging from 94-
98% as compared to gram stain assessment, the current gold standard in assessment[25]. Further 
limitations of the study include the use of a cytobrush for sample collection and the lack of 
histological confirmation for cytology results. Additionally, HPV status was not ascertained for 
participating women.  Last, study participants were recruited from an HIV treatment center, thus 
limiting generalizability of the results to HIV-seropositive women able to seek treatment.  However, 
study participants had a wide range in socioeconomic status markers of education and employment 
with close to 10% of the women receiving 8 or less years of school and 50% being unemployed. Plus, 
access to and obtainment of antiretroviral therapy is expanding rapidly in South Africa. 
There is debate as to the benefits of treating asymptomatic BV in HIV-positive women in 
resource-limited settings.  Based on the lack of association between BV and high grade cervical 
dysplasia and the lack of progression to high grade cervical dysplasia,   treatment of asymptomatic 
BV may not be helpful in reducing the risk of HSIL development in this population.  However further 
research is needed to evaluate BV and vaginal inflammation in the role of HPV and HIV transmission 
and disease course.  
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Table 1. Sociodemographic, lifestyle, and medical characteristics of study participants at study entry 
in the South Africa Cervical Cancer Cohort  
 BV positive BV negative Total study population 
  
 
N=1613*     %† 
 
N=341*   %† N=1954*    %† 
       
Age (median in years, range)      34 (18-65) 
  
    35 (19-61)      34 (18-65) 
Ethnicity         
          African 1034 99.2   871 97.4 1918 98.2 
          Colored/Other 
 
    28   0.8       7   1.7     35   1.8 
Education         
          < Grade 8   255 24.0   201 22.9   463 23.7 
          Grade 8-12   698 65.7   601 68.5 1303 66.7 
          > Grade 12   110 10.4     76   8.7   188  9.6 
Unemployed‡   521 49.0   439 50.0   966 49.4 
CD4 count (median, IQR)   244 (129-382)   253 (144-403)   247 (138-390) 
Trichomoniasis / Candidiasis       
          Yes    119 11.5      45   5.1    164   8.6 
          No    916 88.5    833 94.9 1750 91.4 
Any Current Smoking      49   4.6      25   2.9      74    3.9 
Current Snuff use (times/day)       
          None   958 90.6   792 90.2 1759 90.3 
          1-3     67   6.3     57   6.5   125   6.4 
          >3      33   3.1     29   3.3     63   3.2 
Current Hormonal Contraception      
          Yes   142 13.4   130 14.8   274 14.0 
          No   921 86.6   748 85.2 1680 86.0 
Age at sexual debut (years)       
          <15      94   8.9     65   7.4   160   8.2 
          15–18    644 60.6   530 60.6 1181 60.6 
          19-21    219 20.6   197 22.5   418 21.5 
          >21    105   9.9     82   9.4   189  9.7 
Number of  lifetime partners       
          <5   634 59.8   552 63.2 1189 61.1 
          5-10   325 30.6   268 30.7   602 30.9 
          >10   102   9.6     54   6.2   156   8.0 
Condom use at last act       
          Yes** 1171 73.6   252 69.8 1436 73.5 
          No   412 25.9   105 29.1   517 26.5 
IQR=Interquartile range 
* Numbers may not add up due to missing values 
† Percentages may not add to 100 due to rounding 
‡Employment includes students, pensioners and women on disability 





Table 2. Prevalence ratios of bacterial vaginosis and HSIL+ at study entry in the South Africa 
Cervical Cancer Cohort (N=1954) 






of HSIL+ Crude PR (95% CI) Adjusted PR* (95% CI) 
Bacterial vaginosis         
 
  
  Yes   860   203 18.5% 1.10 (0.91, 1.33) 1.12 (0.92, 1.35) 
  No   725   153 15.7%  1 1 
  Missing       7       6    
PR=prevalence ratio 
* Model adjusted for CD4 count, age, current smoking, hormone contraceptive use, and prevalent 
trichomoniasis or candidiasis infections. 




Table 3. Incidence density ratio comparing progression of cervical lesions in women with BV at 




time (w-y) Progressed* Crude IDR Adjusted IDR† 
ASC-US/AGC as LSIL      
  BV+ 274 368.83 49 0.98 (0.64, 1.49) 1.00 (0.65, 1.53) 
  BV- 229 279.76 38 1 1 
      
ASC-US/AGC as negative      
 BV+ 274 368.83 39 1.23 (0.74, 2.05) 1.27 (0.76, 2.11) 
 BV- 229 279.76 24 1 1 
      
Excluding ASC-US/AGC     
 BV+ 190 262.40 27 1.85 (0.87, 3.94) 1.78 (0.84, 3.79) 
 BV- 128 161.91 9 1 1 
 
w-y=women-years, IDR=incidence density ratio 
* Considered progression when repeat visit has cytology diagnosis that is higher than at baseline 
(negative to LSIL+, LSIL to HSIL+). 



















Figure 1: Cervical smear showing a ‘clue cell’ where the surface of the cell is covered with 
coccobacilli, consistent with bacterial vaginosis (large arrow). At smaller arrow, a cell consistent with 
a low grade squamous intraepithelial lesion, noted with nuclear enlargement and hyperchromasia 




 1957 baseline participants  
     




 1063 BV+a  878 BV-a  
     
 492 (46.3%) Negative 418 (47.6%)  
 165 (15.5%) ASC-US or AGCb 222 (25.3%)  
 203 (19.1%) LSIL 85 (9.7%)  
 6 (0.6%) ASC-H 15 (1.7%)  
 196 (18.4%) HSIL 136 (15.5%)  
 1 (0.1%) SCC 2 (0.2%)  
 
 
Figure 2. Pap smear diagnosis at study entrance in the South Africa Cervical Cancer Cohort, stratified 
by bacterial vaginosis prevalence 
a13 women were missing information on BV diagnosis 
bOf which 381 cases were ASC-US and 6 cases were AGC 
 
 
 
 
 
 
 
 
 
 
 
  
